Q-omics provides the consensus-scored DHRS13 profile across patient tissues and cancer cell-line models. DHRS13 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, DHRS13 is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, DHRS13 RNA expression shows 19,957 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KICH, and ACC as cancer lineages where DHRS13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DHRS13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DHRS13 survival associations across molecular data types. DHRS13 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DHRS13 RNA expression–survival associations across cancer types. High DHRS13 expression shows unfavorable associations in UVM, LIHC, ACC and KIRP, but favorable associations in KIRC and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for DHRS13 RNA expression.
This table summarizes DHRS13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DHRS13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DHRS13 shows lower tumor expression in KICH and higher tumor expression in LIHC, BLCA, BRCA, LUAD and COAD. The KICH box plot shows higher DHRS13 RNA expression in normal versus tumor tissue (log2 FC = −1.504, t-test p < 0.001).
This table shows molecular features associated with DHRS13 in patient tissues and cancer cell lines. In patient samples, DHRS13 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DHRS13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
